A car-sized camera captures the cosmos.
A car-sized camera captures the cosmos.
The Vera C. Rubin Observatory has released the first images taken by its Legacy Survey of Space and Time (LSST) camera — the largest digital camera ever made — ahead of starting its 10-year survey of the southern sky. You can read up on details about these shots in PetaPixel's report, and more images and video will be released later today following a Rubin Observatory livestream at 11AM ET.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Fox News
an hour ago
- Fox News
White House office tells agencies to apply 'Gold Standard Science' to depoliticize research, restore trust
EXCLUSIVE: The White House Office of Science and Technology on Monday directed federal agencies to implement "gold standard science" principles to depoliticize science and restore public trust, Fox News Digital has learned. White House Office of Science and Technology Policy Director Michael Kratsios sent guidance to federal research agencies Monday morning, incorporating President Donald Trump's executive order on "Restoring Gold Standard Science." Fox News Digital exclusively obtained the guidance sent to federal agencies. President Trump, in May, signed an executive order to restore "Gold Standard Science" as the cornerstone of federal scientific research. "Gold Standard Science" is "reproducible, transparent and falsifiable," according to the order. It is also "subject to unbiased peer review; clear about errors and uncertainties; skeptical of assumptions; collaborative and interdisciplinary; accepting of negative results as positive outcomes; and free from conflicts of interest." The executive order reinstated "the scientific integrity policies" of the first Trump administration and "ensures that science is no longer manipulated or misused to justify political ends." "President Trump's Gold Standard Science EO will transform the conduct and management of federal science, from research design to public communication, in order to strengthen scientific inquiry, rebuild public trust, and ensure the U.S. continues to be the global leader in rigorous, evidence-based science," Kratsios told Fox News Digital. "But federal agencies are only one part of our nation's research ecosystem." Kratsios added, "American universities, scientific journals, industry and philanthropic leaders all have a crucial role in improving the overall quality of research, and we encourage this executive action to serve as a model for the entire scientific enterprise." Kratsios sent the memo to federal agencies Monday morning to provide guidance to federal departments and agencies on implementing gold standard science "in the conduct and management of all aspects of their scientific activities, from research design to public communication." "By adopting these standards, agencies will strengthen scientific inquiry, rebuild public trust, and ensure the United States continues as the global leader in rigorous, evidence-based science," the memo states. Kratsios said that "Gold Standard Science" represents a "commitment to the highest standards of scientific integrity, defined by nine core tenets: reproducible; transparent; communicative of error and uncertainty; collaborative and interdisciplinary; skeptical of its findings and assumptions; structured for falsifiability of hypotheses; subject to unbiased peer review; accepting of negative results as positive outcomes; and without conflicts of interest." "These tenets ensure that federally-supported research and research used in federal decision-making is transparent, rigorous, and impactful, enabling federal decisions to be informed by the most credible, reliable, and impartial scientific evidence available," Kratsios wrote in the guidance. But "Gold Standard Science" is not limited to science, Kratsios said, saying that it is critical for tackling complex challenges in energy innovation and national security as well. "In an age of rapid technological progress and heightened public scrutiny, federally-funded and federally-performed science, and its use in Federal decision-making, must be beyond reproach," he wrote. As for conducting science "without conflicts of interest," Kratsios said it is imperative to ensure that "research is designed, executed, reviewed, and reported free from financial, personal, or institutional influences that could bias outcomes or undermine objectivity." "This approach is important for generating trustworthy and credible new knowledge, as it upholds scientific integrity, fosters public confidence, and ensures that results reflect evidence rather than external agendas," the memo states. "Maintaining freedom from conflicts of interest requires researchers, reviewers, and managers to disclose all relevant affiliations, funding sources, and relationships relevant to the science conducted, adhering to stringent ethical standards supported by strong institutional oversight, transparent reporting systems, and independent expert review mechanisms." Kratsios said agencies must "prioritize conducting and managing scientific research free from conflicts of interest to advance unbiased science," and must "require disclosure of all relevant conflicts of interest by researchers, reviewers, and agency officials involved in the funding or performance of Federal research." "These efforts include requiring comprehensive, standardized disclosure of all financial, personal, or institutional interests in research proposals, publications, peer and merit reviews, and data repositories, with clear and standardized protocols to identify, mitigate, and manage potential biases," the memo states. "Agencies should mandate the use of independent oversight approaches and enforce strict conflict-of-interest policies." Agencies have 60 days to outline "Gold Standard Science" implementation plans, including plans for training and resources to ensure agency personnel understand the new policy, and the use of artificial intelligence-driven tools when practical. After Trump signed the May executive order to restore gold standard science, a senior White House official said there had been a decline in "disruptive research" and investments in biomedical research, along with "serious cases" of fraud and misconduct and the inability to reproduce scientific methods for the purpose of restoring public trust. The official also blamed policy responses to the COVID-19 pandemic and "woke DEI initiatives" for endangering the public's trust in government scientists. Now-retired National Institute of Allergy and Infectious Diseases Director Dr. Anthony Fauci was repeatedly denounced for flip-flopping and obfuscating during his time engineering the federal response to COVID-19, leading many, particularly on the right, to disregard and dismiss the legitimacy of federal health authorities outright. That order cites the fact the Biden administration included political edits from teachers' unions in school-reopening guidance, instead of leading with any scientific evidence. Meanwhile, in an exclusive interview with Fox News Digital in April, Kratsios echoed Trump, saying the U.S. is in the "golden age" and that this special moment in time is "underpinned by unbelievable science and technology."
Yahoo
an hour ago
- Yahoo
Arrowhead Pharmaceuticals Completes Enrollment in SHASTA-3, SHASTA-4, and MUIR-3 Phase 3 Studies of Plozasiran
- Study completion anticipated in mid-2026 with subsequent data readout and regulatory submissions for treatment of severe hypertriglyceridemia PASADENA, Calif., June 23, 2025--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has completed enrollment in SHASTA-3, SHASTA-4, and MUIR-3, the company's global Phase 3 clinical studies designed to support regulatory submissions for marketing approval of investigational plozasiran in the treatment of severe hypertriglyceridemia. Arrowhead anticipates completing the primary portion of these studies in mid-2026 with topline data expected shortly thereafter and planned submissions for regulatory review and potential approval to follow. The company previously submitted a New Drug Application (NDA) for plozasiran based on positive Phase 3 PALISADE study results in patients with familial chylomicronemia syndrome, which the U.S. FDA has accepted with a Prescription Drug User Fee Act (PDUFA) action date set for November 18, 2025. "Completion of enrollment for the SHASTA-3, SHASTA-4, and MUIR-3 studies represent important milestones for plozasiran," said Bruce Given, M.D., Chief Medical Scientist at Arrowhead. "These studies bring us closer to generating the datasets needed to support potential global regulatory submissions for plozasiran as a treatment for severe hypertriglyceridemia, pending positive results. With a primary endpoint focused on triglyceride reduction at 12 months, we remain on track for study completion by mid-2026. Arrowhead's clinical development, clinical operations, and regulatory teams continue to execute complex global clinical studies with speed and precision. We owe the entire team involved a debt of gratitude for efficiently initiating these studies in 24 countries and enrolling approximately 2,200 patients. We're grateful to the investigators, caregivers, and patients for participating in these clinical studies, and we thank them for their trust in Arrowhead and in plozasiran." About Severe Hypertriglyceridemia Severe hypertriglyceridemia (SHTG) is characterized by triglyceride (TG) levels greater than 500 mg/dL, with the most severe form being familial chylomicronemia syndrome (FCS) where TGs typically exceed 880 mg/dL. SHTG significantly increases the risk of acute pancreatitis (AP), which can often include recurrent attacks requiring repeat hospital admissions and worsening outcomes. AP risk is proportional to the number, characteristics, and concentration of triglyceride rich lipoproteins (TRLs), particularly chylomicrons, and increases as TGs rise. Elevated TGs can also increase the risk of atherosclerotic cardiovascular disease (ASCVD). Limited treatment options exist to sustainably reduce TGs below guideline directed risk thresholds. About SHASTA-3 and SHASTA-4 Phase 3 Studies SHASTA-3 (NCT06347003) and SHASTA-4 (NCT06347016) are double-blind, placebo-controlled, Phase 3 studies to evaluate the efficacy and safety of plozasiran in adults with severe hypertriglyceridemia. Between the two studies, approximately 750 participants were randomized to receive 4 doses (once every 3 months) of 25 mg plozasiran or placebo. The primary endpoint is percent change in fasting serum triglyceride levels from baseline to month 12 compared to placebo. After month 12, eligible participants will be offered an opportunity to continue in an optional open-label extension. About MUIR-3 Phase 3 Study MUIR-3 (NCT06347133) is a double-blind, placebo-controlled, Phase 3 study to evaluate the efficacy and safety of plozasiran in adults with hypertriglyceridemia (TGs greater than 150 mg/dL and less than 500 mg/dL). Approximately 1,450 participants were randomized to receive 4 doses (once every 3 months) of 25 mg plozasiran or placebo. The primary endpoint is percent change in fasting serum triglyceride levels from baseline to month 12 compared to placebo. About Plozasiran Plozasiran, previously called ARO-APOC3, is a first-in-class investigational RNA interference (RNAi) therapeutic designed to reduce production of apolipoprotein C-III (APOC3) which is a component of triglyceride rich lipoproteins (TRLs) and a key regulator of triglyceride metabolism. APOC3 increases triglyceride levels in the blood by inhibiting breakdown of TRLs by lipoprotein lipase and uptake of TRL remnants by receptors in the liver. The goal of treatment with plozasiran is to reduce the level of APOC3, thereby reducing triglycerides and restoring lipids to more normal levels. In multiple clinical studies, investigational plozasiran has demonstrated reductions in triglycerides and multiple atherogenic lipoproteins in patients with familial chylomicronemia syndrome (FCS), severe hypertriglyceridemia (SHTG), and mixed hyperlipidemia. Plozasiran has been generally well tolerated to date with treatment emergent adverse events reported that generally reflect the comorbidities and underlying conditions of the study populations. Across clinical studies and study populations, the most frequently reported treatment emergent adverse events for the 25 mg dose that is proposed for marketing approval were COVID-19, upper respiratory tract infection, headache, Type 2 diabetes mellitus, and abdominal pain. Plozasiran is being investigated in the SUMMIT program of clinical studies, including the PALISADE Phase 3 study in patients with FCS, the SHASTA studies in patients with SHTG, and the MUIR studies in patients with mixed hyperlipidemia. Plozasiran in the treatment of patients with FCS has been granted Breakthrough Therapy Designation, Orphan Drug Designation, and Fast Track Designation by the U.S. Food and Drug Administration and Orphan Medicinal Product Designation by the European Medicines Agency. Investigational plozasiran has been submitted for marketing authorization in treatment of FCS to multiple global regulatory authorities but has not been reviewed or approved to treat any disease. About Arrowhead Pharmaceuticals, Inc. Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead's RNAi-based therapeutics leverage this natural pathway of gene silencing. For more information, please visit or follow us on X (formerly Twitter) at @ArrowheadPharma, LinkedIn, Facebook, and Instagram. To be added to the Company's email list and receive news directly, please visit Safe Harbor Statement under the Private Securities Litigation Reform Act: This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this release except for historical information may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "might," "will," "expect," "believe," "anticipate," "goal," "endeavor," "strive," "hope," "intend," "plan," "project," "could," "estimate," "potential," "target," "forecast" or "continue" or the negative of these words or other variations thereof or comparable terminology are intended to identify such forward-looking statements. In addition, any statements that refer to projections of our future financial performance, trends in our business, expectations for our product pipeline or product candidates, including anticipated regulatory submissions and clinical program results, prospects or benefits of our collaborations with other companies, or other characterizations of future events or circumstances are forward-looking statements. These forward-looking statements include, but are not limited to, statements about the initiation, timing, progress and results of our preclinical studies and clinical trials, and our research and development programs; our expectations regarding regulatory approval for and commercial launch of plozasiran; our expectations regarding the potential benefits of the partnership, licensing and/or collaboration arrangements and other strategic arrangements and transactions we have entered into or may enter into in the future; our beliefs and expectations regarding milestone, royalty or other payments that could be due to or from third parties under existing agreements; and our estimates regarding future revenues, research and development expenses, capital requirements and payments to third parties. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of numerous factors and uncertainties, including the safety and efficacy of our product candidates, decisions of regulatory authorities and the timing thereof, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, the enforcement of our intellectual property rights, and the other risks and uncertainties described in our most recent Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and other documents filed with the Securities and Exchange Commission from time to time. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances. Source: Arrowhead Pharmaceuticals, Inc. View source version on Contacts Arrowhead Pharmaceuticals, Anzalone, CFA626-304-3400ir@ Investors: LifeSci Advisors, LLCBrian Ritchie 212-915-2578britchie@ Media: LifeSci Communications, LLCKendy Guarinoni, Ph.D.724-910-9389kguarinoni@
Forbes
an hour ago
- Forbes
Women In Engineering: Climate Impact And The Call For More Equity
Engineer at solar station. As the world races to meet net-zero targets, the role of women engineers has never been more critical. Today we celebrate International Women in Engineering Day 2025, under the theme 'Together We Engineer.' Female engineers have been impactful in renewable energy systems, sustainable infrastructure. Women are designing, building, and maintaining the future of our planet. The Numbers Show That We Need More Women in Engineering According to a UNESCO Science Report, women account for just 28% of engineering graduates globally. In the United States, only 13.7% of the engineering workforce are women, according to an Engineer Choice report. The underrepresentation is stark, however there is a lot of effort being made to increase these numbers globally through STEM clubs and books that introduce girls to different STEM fields including engineering. There are also engineers in the sustainability space like Rose Mutiso, who is the Research Director at the Energy for Growth Hub, whose work bridges energy equity and climate resilience across Sub-Saharan Africa through tailored infrastructure and policy innovation. According to IRENA's 2023 report, over 13 million people worked in renewable energy in 2022, yet only 32% were women, and most of those were in non-technical roles. In order to accelerate climate solutions, we must increase female participation in core engineering and energy leadership positions as women bring a different perspective to the sector that they are involved in. The professionals designing solar microgrids, optimizing battery storage, and advancing hydrogen and geothermal systems are vital to our future, and women are excelling in these roles. They bring not just technical expertise, but also empathy-led design, community-centered solutions, and systems thinking. These qualities are essential for building resilient, inclusive, and sustainable infrastructure. A McKinsey & Company study found that companies with higher gender diversity had 36% more revenue from innovation compared to those who do not. Additionally women are also underrepresented at all levels of the corporate pipeline. Equity is not a checkbox, it is a catalyst for innovation. Women Moving from Recognition to Action Climate change is not gender neutral. According to the United Nations, 80% of people displaced by climate change are women, due to their disproportionate reliance on natural resources, caregiving roles, and limited access to economic and decision-making power. In low-income and rural communities, women are often responsible for food, water, and fuel collection, which are becoming increasingly scarce due to climate-related disasters. Coupled with this, these intersecting vulnerabilities compound the risk of climate-driven social and economic instability. As a result, climate action must therefore be inclusive by design, with policies and technologies that protect and empower the most affected. Companies, governments, and academia must invest in mentorship, scholarships, and structural reforms to ensure the pipeline of female talent not only opens but flows and thrives. On this International Women in Engineering Day, we should pause and honor the women already engineering change and commit to empowering the ones of the future because, together, we engineer not just systems but a sustainable future.
